Cardiovascular disease and risk management: Review of the American diabetes association standards of medical care in diabetes 2018

Annals of Internal Medicine

Volumn 168, Issue 9, 2018, Pages 640-650

  Chamberlain, James J ^a   Johnson, Eric L ^b   Leal, Sandra ^c   Rhinehart, Andrew S ^d   Shubrook, Jay H ^e   Peterson, Lacie ^f  

^a St Mark's Hospital Salt Lake City   (United States)

^b UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c SinfoniaRx   (United States)

^d Glytec LLC   (United States)

^e Touro University California   (United States)

^f UTAH STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANAGLIFLOZIN; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NICOTINIC ACID; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR ANTAGONIST; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; EVIDENCE BASED MEDICINE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; NATIONAL HEALTH ORGANIZATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK MANAGEMENT; ADULT; BLOOD PRESSURE MONITORING; CORONARY ARTERY DISEASE; DIABETIC ANGIOPATHY; DYSLIPIDEMIA; HEALTH CARE QUALITY; HEALTHY LIFESTYLE; RISK FACTOR;

ADULT; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BLOOD PRESSURE MONITORING, AMBULATORY; CORONARY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; HEALTHY LIFESTYLE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; HYPOGLYCEMIC AGENTS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; RISK MANAGEMENT; STANDARD OF CARE;

EID: 85046405486     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M18-0222     Document Type: Review

References (70)

1. Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017;376:1407-18. [PMID: 28402770] doi:10.1056/NEJMoa1608664
2. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370:1514-23. [PMID: 24738668] doi:10.1056/NEJMoa1310799
3. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356:2388-98. [PMID: 17554120]
4. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017. [PMID: 29146535] doi:10.1016/j.jacc.2017.11.006
5. de Boer IH, Bangalore S, Benetos A, Davis AM, Michos ED, Muntner P, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40:1273-84. [PMID: 28830958] doi:10.2337/dci17-0026
6. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362:1575-85. [PMID: 20228401] doi:10.1056/NEJMoa1001286
7. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015; 373:2103-16. [PMID: 26551272] doi:10.1056/NEJMoa1511939
8. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351:1755-62. [PMID: 9635947]
9. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, et al; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829-40. [PMID: 17765963]
10. Bakris GL. The implications of blood pressure measurement methods on treatment targets for blood pressure. Circulation. 2016; 134:904-5. [PMID: 27576778] doi:10.1161/CIRCULATIONAHA.116.022536
11. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-20. [PMID: 24352797] doi:10.1001/jama.2013.284427
12. Valencia WM, Florez H. Pharmacological treatment of diabetes in older people. Diabetes Obes Metab. 2014;16:1192-203. [PMID: 25073699] doi:10.1111/dom.12362
13. Cespedes EM, Hu FB, Tinker L, Rosner B, Redline S, Garcia L, et al. Multiple healthful dietary patterns and type 2 diabetes in the Women's Health Initiative. Am J Epidemiol. 2016;183:622-33. [PMID: 26940115] doi:10.1093/aje/kwv241
14. Bray GA, Vollmer WM, Sacks FM, Obarzanek E, Svetkey LP, Appel LJ; DASH Collaborative Research Group. A further subgroup analysis of the effects of the DASH diet and three dietary sodium evels on blood pressure: results of the DASH-Sodium Trial. Am J Cardiol. 2004;94:222-7. [PMID: 15246908]
15. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129:S76-99. [PMID: 24222015] doi:10.1161/01.cir.0000437740.48606.d1
16. Thomas MC, Moran J, Forsblom C, Harjutsalo V, Thorn L, Ahola A, et al; FinnDiane Study Group. The association between dietary sodium intake, ESRD, and all-cause mortality in patients with type 1 diabetes. Diabetes Care. 2011;34:861-6. [PMID: 21307382] doi:10.2337/dc10-1722
17. Ekinci EI, Clarke S, Thomas MC, Moran JL, Cheong K, MacIsaac RJ, et al. Dietary salt intake and mortality in patients with type 2 diabetes. Diabetes Care. 2011;34:703-9. [PMID: 21289228] doi:10.2337/dc10-1723
18. Sacks FM, Lichtenstein AH, Wu JHY, Appel LJ, Creager MA, Kris-Etherton PM, et al; American Heart Association. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. Circulation. 2017;136:e1-23. [PMID: 28620111] doi:10.1161/CIR.0000000000000510
19. Harris WS, Mozaffarian D, Rimm E, Kris-Etherton P, Rudel LL, Appel LJ, et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation. 2009;119:902-7. [PMID: 19171857] doi:10.1161/CIRCULATIONAHA.108.191627
20. Crochemore IC, Souza AF, de Souza AC, Rosado EL. ω-3 polyunsaturated fatty acid supplementation does not influence body composition, insulin resistance, and lipemia in women with type 2 diabetes and obesity. Nutr Clin Pract. 2012;27:553-60. [PMID: 22661243] doi:10.1177/0884533612444535
21. Holman RR, Paul S, Farmer A, Tucker L, Stratton IM, Neil HA; Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes Study Group. Atorvastatin in factorial with omega-3 EE90 risk reduction in diabetes (AFORRD): a randomised controlled trial. Diabetologia. 2009;52:50-9. [PMID: 19002433] doi:10.1007/s00125-008-1179-5
22. Kromhout D, Geleijnse JM, de Goede J, Oude Griep LM, Mulder BJ, de Boer MJ, et al. n-3 fatty acids, ventricular arrhythmia-related events, and fatal myocardial infarction in postmyocardial infarction patients with diabetes. Diabetes Care. 2011;34:2515-20. [PMID: 22110169] doi:10.2337/dc11-0896
23. Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, et al; ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309-18. [PMID: 22686415] doi:10.1056/NEJMoa1203859
24. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al; PREDIMED Study Investigators. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368: 1279-90. [PMID: 23432189] doi:10.1056/NEJMoa1200303
25. Brehm BJ, Lattin BL, Summer SS, Boback JA, Gilchrist GM, Jandacek RJ, et al. One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. Diabetes Care. 2009;32:215-20. [PMID: 18957534] doi:10.2337/dc08-0687
26. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, et al; Dietary Intervention Randomized Controlled Trial (DIRECT) Group. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med. 2008;359:229-41. [PMID: 18635428] doi:10.1056/NEJMoa0708681
27. Brunerova L, Smejkalova V, Potockova J, Andel M. A comparison of the influence of a high-fat diet enriched in monounsaturated fatty acids and conventional diet on weight loss and metabolic parameters in obese non-diabetic and type 2 diabetic patients. Diabet Med. 2007;24:533-40. [PMID: 17381504]
28. Bloomfield HE, Koeller E, Greer N, MacDonald R, Kane R, Wilt TJ. Effects on health outcomes of a Mediterranean diet with no restriction on fat intake: a systematic review and meta-analysis. Ann Intern Med. 2016;165:491-500. [PMID: 27428849] doi:10.7326/M16-0361
29. Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, et al; NLA Expert Panel. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9:S1-122. [PMID: 26699442] doi:10.1016/j.jacl.2015.09.002
30. Lam T, Burns K, Dennis M, Cheung NW, Gunton JE. Assessment of cardiovascular risk in diabetes: risk scores and provocative testing. World J Diabetes. 2015;6:634-41. [PMID: 25987961] doi:10.4239/wjd.v6.i4.634
31. Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581-90. [PMID: 22607822] doi: 10.1016/S0140-6736(12)60367-5
32. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78. [PMID: 16214597]
33. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005-16. [PMID: 12814710]
34. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013:CD004816. [PMID: 23440795] doi:10.1002/14651858.CD004816.pub5
35. Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610. [PMID: 23704171] doi:10.1136/bmj.f2610
36. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, et al. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care. 2006;29:1220-6. [PMID: 16731999]
37. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-504. [PMID: 15007110]
38. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372: 2387-97. [PMID: 26039521] doi:10.1056/NEJMoa1410489
39. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713-22. [PMID: 28304224] doi:10.1056/NEJMoa1615664
40. Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccara-Dinet MT, et al. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J Clin Lipidol. 2014;8:554-61. [PMID: 25499937] doi:10.1016/j.jacl.2014.09.007
41. Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li GN, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123. [PMID: 26099511] doi:10.1186/s12916-015-0358-8
42. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al; Endocrine Society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969-89. [PMID: 22962670] doi:10.1210/jc.2011-3213
43. Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al; ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-74. [PMID: 20228404] doi:10.1056/NEJMoa1001282
44. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255-67. [PMID: 22085343] doi:10.1056/NEJMoa1107579
45. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care. 2009;32:1924-9. [PMID: 19794004] doi:10.2337/dc09-0738
46. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735-42. [PMID: 20167359] doi:10.1016/S0140-6736(09)61965-6
47. Ridker PM, Pradhan A, MacFadyen JG, Libby P, Glynn RJ. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565-71. [PMID: 22883507] doi:10.1016/S0140-6736(12)61190-8
48. Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, et al. Statins and cognitive function: a systematic review. Ann Intern Med. 2013;159:688-97. [PMID: 24247674] doi:10.7326/0003-4819-159-10-201311190-00007
49. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al; Antithrombotic Trialists' (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849-60. [PMID: 19482214] doi:10.1016/S0140-6736(09)60503-1
50. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al; European Association for Cardiovascular Prevention & Rehabilitation (EACPR). European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J. 2012;33:1635-701. [PMID: 22555213] doi:10.1093/eurheartj/ehs092
51. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al; Prevention of Progression of Arterial Disease and Diabetes Study Group. The Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840. [PMID: 18927173] doi:10.1136/bmj.a1840
52. Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2010;87:211-8. [PMID: 19853947] doi:10.1016/j.diabres.2009.09.029
53. De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531. [PMID: 19897665] doi:10.1136/bmj.b4531
54. Bibbins-Domingo K; U.S. Preventive Services Task Force. Aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2016;164:836-45. [PMID: 27064677] doi: 10.7326/M16-0577
55. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA. 2007;297:2018-24. [PMID: 17488967]
56. Vandvik PO, Lincoff AM, Gore JM, Gutterman DD, Sonnenberg FA, Alonso-Coello P, et al. Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141:e637S-68S. [PMID: 22315274] doi:10.1378/chest.11-2306
57. Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67:2732-40. [PMID: 27046160] doi:10.1016/j.jacc.2016.03.529
58. Bax JJ, Young LH, Frye RL, Bonow RO, Steinberg HO, Barrett EJ; ADA. Screening for coronary artery disease in patients with diabetes. Diabetes Care. 2007;30:2729-36. [PMID: 17901530]
59. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al; COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356:1503-16. [PMID: 17387127]
60. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, et al; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503-15. [PMID: 19502645] doi:10.1056/NEJMoa.0805796
61. Wackers FJ, Young LH, Inzucchi SE, Chyun DA, Davey JA, Barrett EJ, et al; Detection of Ischemia in Asymptomatic Diabetics Investigators. Detection of silent myocardial ischemia in asymptomatic diabetic subjects: the DIAD study. Diabetes Care. 2004;27:1954-61. [PMID: 15277423]
62. Scognamiglio R, Negut C, Ramondo A, Tiengo A, Avogaro A. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2006;47:65-71. [PMID: 16386666]
63. Braunwald E, Domanski MJ, Fowler SE, Geller NL, Gersh BJ, Hsia J, et al; PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351: 2058-68. [PMID: 15531767]
64. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, Copland I, et al; Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet. 2008;372: 1174-83. [PMID: 18757085] doi:10.1016/S0140-6736(08)61242-8
65. Kezerashvili A, Marzo K, De Leon J. Beta blocker use after acute myocardial infarction in the patient with normal systolic function: when is it "ok" to discontinue? Curr Cardiol Rev. 2012;8:77-84. [PMID: 22845818]
66. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28. [PMID: 26378978] doi:10.1056/NEJMoa.1504720
67. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al; LEADER Steering Committee. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016; 375:311-22. [PMID: 27295427] doi:10.1056/NEJMoa1603827
68. Neal B, Perkovic V, Matthews DR, Mahaffey KW, Fulcher G, Meininger G, et al; CANVAS-R Trial Collaborative Group. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): a randomized, placebo-controlled trial. Diabetes Obes Metab. 2017;19:387-93. [PMID: 28120497] doi:10.1111/dom.12829
69. Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, et al; Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369: 145-54. [PMID: 23796131] doi:10.1056/NEJMoa1212914
70. Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015;115:1447-63. [PMID: 25935570] doi:10.1016/j.jand.2015.02.031